In women with hormone-sensitive breast cancer who want to become mothers, pausing endocrine therapy to try to get pregnant for up to two years does not increase the risk of short-term relapse. This is supported by the results of the Positive clinical trial, published in The New England Journal of Medicine.
It is estimated that between 40% and 60% of patients diagnosed with breast cancer at age 40 or earlier are concerned about their future fertility. The results show rates of conception and delivery that are on par with or higher than those of the general population.